

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 6, 2018**

---

**KURA ONCOLOGY, INC.**

(Exact name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-37620**  
(Commission File Number)

**61-1547851**  
(IRS Employer  
Identification No.)

**3033 Science Park Road, Suite 220, San Diego, CA**  
(Address of Principal Executive Offices)

**92121**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (858) 500-8800**

**N/A**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 6, 2018, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Mary Szela as a Class III director of the Company, with a term of office expiring at the 2020 annual meeting of stockholders. There are no arrangements or understandings between Ms. Szela and any other person pursuant to which she was selected as a director. In addition, there are no transactions in which Ms. Szela has an interest that would require disclosure under Item 404(a) of Regulation S-K.

Pursuant to the Company’s Amended and Restated Non-Employee Director Compensation Policy (the “Compensation Policy”), Ms. Szela (i) will receive an annual cash retainer of \$38,000 for service on the Board, and (ii) was granted on the date of her appointment an option to purchase (a) 30,000 shares of the Company’s common stock, which vests annually over a three year period, and (b) 7,583 shares of the Company’s common stock, which vests in full on the one year anniversary of the date of grant. The Compensation Policy also provides for further automatic annual option grants to purchase 13,000 shares of the Company’s common stock on the date of each annual meeting of stockholders, which vest in full on the one year anniversary of the date of grant. Each of the option grants described above will vest in full in the event of a change in control (as defined in the Company’s equity incentive plan). Ms. Szela has also entered into the Company’s standard form of Indemnification Agreement.

The Company issued a press release announcing the appointment of Ms. Szela, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<b>Exhibit Number</b>	<b>Description</b>
99.1	<u>Press release issued by Kura Oncology, Inc. on November 8, 2018</u>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**KURA ONCOLOGY, INC.**

Date: November 8, 2018

By: \_\_\_\_\_ /s/ Annette North  
**Annette North**  
**Senior Vice President and General Counsel**



## Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors

– Ms. Szela brings expertise in global brand development to Kura as company enters first registration-directed trial –

**SAN DIEGO, November 8, 2018** – Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the appointment of commercial veteran Mary Szela to its board of directors. Throughout her 30-year career in the biopharmaceutical industry, Ms. Szela has served on a number of high-profile boards, developed global brands and led the world’s largest selling pharmaceutical product, Humira®, through the launch of five indications.

“Mary’s strategic vision and track record in the commercial arena make her a valuable addition to our board,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “Her appointment is especially timely given the initiation of a global, registration-directed trial of our lead drug candidate, tipifarnib, announced earlier this week. Mary brings extensive experience in marketing, business development, strategic planning and implementation, all of which will be important as we prepare to incorporate commercial planning into our strategy and operations.”

Ms. Szela joins the Kura Oncology board of directors with significant experience serving on the boards of publicly traded biopharmaceutical companies, including Receptos, acquired by Celgene for \$7.2 billion in July 2015, and Novo Nordisk, a Danish multinational pharmaceutical company. She currently serves on the board of Coherus Biosciences, Alimera Sciences and TriSalus Life Sciences.

“I am very excited to join the board of Kura at such a critical time for the company,” said Ms. Szela. “With an initial, registration-directed trial now underway for tipifarnib and a third drug candidate poised to enter the clinic, the company is well situated with a deep pipeline, a proven management team and a strong cash position. I look forward to working with the company’s leadership and other members of the board to help the company advance these promising drug candidates and achieve its strategic objectives.”

Ms. Szela is currently the Chief Executive Officer and President of TriSalus Life Sciences, a company developing technologies to deliver immune oncology agents to solid tumors in high mortality cancers. Previously, she was Chief Executive Officer of Novelion Therapeutics, where she executed the merger of Aegerion Pharmaceuticals and QLT Therapeutics, and Melinta Therapeutics. Earlier, Ms. Szela spent 25 years at

---

Abbott Laboratories, where she held a number of ascending leadership positions, including President of Abbott's \$8 billion U.S. Pharmaceuticals business. Ms. Szela earned an MBA and a bachelor's degree in nursing from the University of Illinois.

## **About Kura Oncology**

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura's lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, for which the Company has initiated a registration-directed trial of tipifarnib recurrent or metastatic patients with HRAS mutant head and neck squamous cell carcinomas. In addition, tipifarnib is being evaluated in multiple other Phase 2 clinical trials in solid tumor and hematologic indications. Kura's pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in IND-enabling studies. For additional information about Kura Oncology, please visit the Company's website at [www.kuraoncology.com](http://www.kuraoncology.com).

## **Forward-Looking Statements**

*This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of tipifarnib and the Company's other product candidates, the conduct, results and timing of Kura Oncology's clinical trials, plans regarding future clinical trials and development and commercial activities, the regulatory approval path for tipifarnib and the adequacy of cash on hand. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura Oncology may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "promise," "potential," "expects," "plans," "anticipated," "intends," "continues," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are*

---

*available at [www.sec.gov](http://www.sec.gov). Such forward-looking statements are current only as of the date they are made, and Kura Oncology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.*

## **Contacts**

### Company:

Pete De Spain

Vice President, Investor Relations &

Corporate Communications

(858) 500-8803

[pete@kuraoncology.com](mailto:pete@kuraoncology.com)

### Investors:

Robert H. Uhl

Managing Director

Westwicke Partners, LLC

(858) 356-5932

[robert.uhl@westwicke.com](mailto:robert.uhl@westwicke.com)

### Media:

Jason Spark

Managing Director

Canale Communications

(619) 849-6005

[jason@canalecomm.com](mailto:jason@canalecomm.com)